{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:27:51Z","timestamp":1770517671727,"version":"3.49.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.2169\/internalmedicine.5764-25","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T22:07:46Z","timestamp":1752098866000},"page":"386-395","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Efficacy of Dapagliflozin in Cases of Advanced Renal Dysfunction in Chronic Kidney Disease"],"prefix":"10.2169","volume":"65","author":[{"given":"Yoshihiko","family":"Imamura","sequence":"first","affiliation":[{"name":"Department of Nephrology, Nissan Tamagawa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nissan Tamagawa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nissan Tamagawa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nissan Tamagawa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Masaki T, Hanafusa N, Abe M, et al. 2023 Annual dialysis data report, JSDT renal data registry. Nihon Toseki Igakkai Zasshi (J Jpn Soc Dial Ther) 57: 543-620, 2024 (in Japanese).","DOI":"10.4009\/jsdt.57.543"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nagai K, Asahi K, Iseki K, Yamagata K. Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. Clin Exp Nephrol 25: 885-892, 2021.","DOI":"10.1007\/s10157-021-02049-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al.; the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436-1446, 2020.","DOI":"10.1056\/NEJMoa2024816"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. List JF, Tand W, Woo V, Morales E, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650-657, 2009.","DOI":"10.2337\/dc08-1863"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Koshino A, Schecher M, Chertow GM, et al. Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid 2: EVIDoa2300049, 2023.","DOI":"10.1056\/EVIDoa2300049"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Matsuo S, Imai E, Horio M, et al.; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Imamura Y, Takahashi Y, Hayashi T, et al. Usefulness of multidisciplinary care to prevent worsening renal function in chronic kidney disease. Clin Exp Nephrol 23: 484-492, 2019.","DOI":"10.1007\/s10157-018-1658-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Imamura Y, Takahashi Y, Takeuchi T, et al. Relationship between compliance with management target values and renal prognosis in multidisciplinary care for outpatients with chronic kidney disease. Clin Exp Nephrol 26: 750-759, 2022.","DOI":"10.1007\/s10157-022-02215-y"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134: 752-772, 2016.","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ghanim H, Abuaysheh S, Hejna J, et al. Dapagli\ufb02ozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 105: e1056-e1063, 2020.","DOI":"10.1210\/clinem\/dgaa057"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mazer CD, Hare GMT, Connelly PW, et al. Effect of empagli\ufb02ozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 141: 704-707, 2020.","DOI":"10.1161\/CIRCULATIONAHA.119.044235"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhao Y, Xu L, Tian D, et al. Effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 20: 458-462, 2018.","DOI":"10.1111\/dom.13101"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jongs N, Greene T, Chertow GM, et al.; the DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9: 755-766, 2021.","DOI":"10.1016\/S2213-8587(21)00243-6"},{"key":"14","unstructured":"14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3: 63-72, 2013."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sada K, Hidaka S, Kashima J, Morita M, Sada K, Shibata H. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function. J Diabetes Investig 13: 1330-1338, 2022.","DOI":"10.1111\/jdi.13795"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chertow GM, Vart P, Jongs N, et al.; the DAPA-CKD Trial Committees and Investigators. Effects of dapagli\ufb02ozin in stage 4 chronic kidney disease. J Am Soc Nephrol 32: 2352-2361, 2021.","DOI":"10.1681\/ASN.2021020167"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shi Y, Xiong J, Chen Y, et al. The effectiveness of multidisciplinary care models for patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 50: 301-312, 2018.","DOI":"10.1007\/s11255-017-1679-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Machida S, Shibagaki Y, Sakurada T. An inpatient educational program for chronic kidney disease. Clin Exp Nephrol 23: 493-500, 2019.","DOI":"10.1007\/s10157-018-1660-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yoshida K, Shimizu S, Kita Y, Takagi WH, Shibagaki Y, Sakurada T. Impact of inpatient educational programs on mortality after the start of dialysis therapy. Clin Exp Nephrol 26: 819-826, 2022.","DOI":"10.1007\/s10157-022-02211-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S. Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study. Clin Exp Nephrol 27: 528-541, 2023.","DOI":"10.1007\/s10157-023-02338-w"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Imamura Y, Takahashi Y, Uchida S, et al. Effect of multidisciplinary care of dialysis initiation for outpatients with chronic kidney disease. Int Urol Nephrol 53: 1435-1444, 2021.","DOI":"10.1007\/s11255-021-02787-w"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/3\/65_5764-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:47:05Z","timestamp":1770436025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/3\/65_5764-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5764-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"article-number":"5764-25"}}